Pancreatic Cancer Research

ResearcherUniversity of TsukubaActive in the last 2 years

Ichinosuke Hyodo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8210-0731; OpenAlex author ID A5112855518. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
45
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers

Papers 7

  1. A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable advanced pancreatic cancer treated with firs… Co-author DOI 10.1007/s10147-025-02717-1↗
  2. Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2025.06.010↗
  3. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer. Last author DOI 10.2169/internalmedicine.8736-21↗
  4. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. Co-author DOI 10.1097/md.0000000000027591↗
  5. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Last author DOI 10.1016/j.ejca.2018.10.004↗
  6. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  7. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Last author DOI 10.1038/bjc.2015.103↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuhito Koizumi · 4 shared papers, 2021–2025 · strength 0.67
  2. Yoichi Hiasa · 4 shared papers, 2021–2025 · strength 0.67
  3. Akinori Asagi · 3 shared papers, 2022–2025 · strength 0.56
  4. Yoshinori Ohno · 3 shared papers, 2021–2025 · strength 0.56
  5. Toru Otsuru · 2 shared papers, 2025 · strength 0.45
  6. Teru Kumagi · 3 shared papers, 2021–2025 · strength 0.43
  7. Kaori Hino · 2 shared papers, 2022–2025 · strength 0.32
  8. Taira Kuroda · 2 shared papers, 2021–2025 · strength 0.31
  9. Takashi Terao · 2 shared papers, 2021–2022 · strength 0.23
  10. Yuki Numata · 1 shared paper, 2025 · strength 0.20
  11. Shoji Nakamori · 3 shared papers, 2015–2019 · strength 0.15
  12. Masafumi Ikeda · 3 shared papers, 2015–2019 · strength 0.15
  13. Takuji Okusaka · 3 shared papers, 2015–2019 · strength 0.15
  14. Nobumasa Mizuno · 2 shared papers, 2016–2019 · strength 0.11
  15. Tatsuya Ioka · 2 shared papers, 2016–2019 · strength 0.11
  16. Masayuki Furukawa · 2 shared papers, 2016–2019 · strength 0.11
  17. Narikazu Boku · 2 shared papers, 2016–2019 · strength 0.11
  18. Junji Furuse · 2 shared papers, 2016–2019 · strength 0.11
  19. Nobuaki Azemoto · 1 shared paper, 2021 · strength 0.11
  20. Yoshinori Tanaka · 1 shared paper, 2021 · strength 0.11
  21. Akira Fukutomi · 2 shared papers, 2015–2016 · strength 0.08
  22. Hiroyuki Isayama · 2 shared papers, 2015–2016 · strength 0.08
  23. Hideo Baba · 2 shared papers, 2015–2016 · strength 0.08
  24. Taketo Yamaguchi · 1 shared paper, 2019 · strength 0.07
  25. Masashi Kanai · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.